NASDAQ:ALPN Alpine Immune Sciences (ALPN) Stock Forecast, Price & News $11.98 +0.46 (+3.99%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$11.47▼$12.2050-Day Range$11.42▼$13.9852-Week Range$4.82▼$14.92Volume143,496 shsAverage Volume161,101 shsMarket Capitalization$589.42 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Alpine Immune Sciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside50.3% Upside$18.00 Price TargetShort InterestBearish5.12% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.18) to ($1.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.60 out of 5 starsMedical Sector868th out of 961 stocksPharmaceutical Preparations Industry410th out of 451 stocks 3.5 Analyst's Opinion Consensus RatingAlpine Immune Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.00, Alpine Immune Sciences has a forecasted upside of 50.3% from its current price of $11.98.Amount of Analyst CoverageAlpine Immune Sciences has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted5.12% of the outstanding shares of Alpine Immune Sciences have been sold short.Short Interest Ratio / Days to CoverAlpine Immune Sciences has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.Change versus previous monthShort interest in Alpine Immune Sciences has recently increased by 28.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlpine Immune Sciences does not currently pay a dividend.Dividend GrowthAlpine Immune Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALPN. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Alpine Immune Sciences this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Alpine Immune Sciences to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alpine Immune Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders42.30% of the stock of Alpine Immune Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.17% of the stock of Alpine Immune Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Alpine Immune Sciences are expected to decrease in the coming year, from ($1.18) to ($1.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alpine Immune Sciences is -8.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alpine Immune Sciences is -8.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlpine Immune Sciences has a P/B Ratio of 3.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Alpine Immune Sciences (NASDAQ:ALPN) StockAlpine Immune Sciences, Inc., a clinical-stage company, focuses on immune therapeutics. The company has strategic collaborations immunotherapies via protein engineering technologies with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept (ALPN-303), which is in a phase 1b, open-label study of povetacicept in autoimmune cytopenias, including immune thrombocytopenia, warm autoimmune hemolytic anemia, and cold agglutinin disease; and in phase 1b/2a, open-label study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, lupus nephritis, and primary membranous nephropathy. The company is also developing Acazicolcept (ALPN-101), which is in a phase 2 study of acazicolcept in patients with Systemic Lupus Erythematosus. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.Read More ALPN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALPN Stock News HeadlinesSeptember 20, 2023 | msn.comHere's Why You Should Invest in Alpine (ALPN) Stock NowSeptember 17, 2023 | americanbankingnews.comAlpine Immune Sciences (NASDAQ:ALPN) Sees Large Volume IncreaseSeptember 26, 2023 | Stansberry Research (Ad)1907, 1929, 1998, 2007--and now 2023?Analyst who called Lehman Bros. collapse says exact same scenario that occurred in 4 of America’s biggest economic calamities is unfolding again now. More here.September 17, 2023 | americanbankingnews.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Sees Significant Increase in Short InterestSeptember 13, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Alpine Immune Sciences (ALPN)September 12, 2023 | finance.yahoo.comAlpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual MeetingSeptember 5, 2023 | finance.yahoo.comAlpine Immune Sciences to Present First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual MeetingAugust 31, 2023 | markets.businessinsider.comAnalyst Expectations for Alpine Immune Sciences's FutureSeptember 26, 2023 | Stansberry Research (Ad)1907, 1929, 1998, 2007--and now 2023?Analyst who called Lehman Bros. collapse says exact same scenario that occurred in 4 of America’s biggest economic calamities is unfolding again now. More here.August 31, 2023 | msn.comAlpine Immune Sciences (ALPN) Price Target Increased by 10.67% to 16.93August 30, 2023 | finance.yahoo.comAlpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)August 24, 2023 | finance.yahoo.comAlpine Immune Sciences, Inc. (ALPN) Is a Great Choice for 'Trend' Investors, Here's WhyAugust 22, 2023 | finance.yahoo.comAlpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)August 17, 2023 | finance.yahoo.comDoes Alpine Immune Sciences, Inc. (ALPN) Have the Potential to Rally 25.38% as Wall Street Analysts Expect?August 16, 2023 | msn.comAlpine Immune Sciences: Going Strong But For How Long?August 16, 2023 | finance.yahoo.comCompanies Like Alpine Immune Sciences (NASDAQ:ALPN) Are In A Position To Invest In GrowthAugust 15, 2023 | msn.comHC Wainwright & Co. Maintains Alpine Immune Sciences (ALPN) Buy RecommendationAugust 15, 2023 | msn.comWedbush Maintains Alpine Immune Sciences (ALPN) Outperform RecommendationAugust 14, 2023 | finance.yahoo.comAlpine Immune Sciences Reports Second Quarter 2023 Financial ResultsJuly 23, 2023 | finance.yahoo.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) surges 14%; private equity firms who own 38% shares profited along with institutionsJune 22, 2023 | finance.yahoo.comAlpine Immune (ALPN) Stock Up 19% MTD, Will the Uptick Continue?June 14, 2023 | markets.businessinsider.comAlpine Immune Sciences (ALPN) Receives a Rating Update from a Top AnalystJune 10, 2023 | fool.comAlpine Immune Sciences (NASDAQ: ALPN)May 19, 2023 | finance.yahoo.comAlpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific CongressesMay 13, 2023 | msn.comAlpine Immune Sciences GAAP EPS of -$0.28 beats by $0.09, revenue of $9.4M beats by $2.52MMay 12, 2023 | msn.comHC Wainwright & Co. Reiterates Alpine Immune Sciences (ALPN) Buy RecommendationMay 11, 2023 | msn.comRecap: Alpine Immune Sciences Q1 EarningsSee More Headlines Receive ALPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ALPN Company Calendar Last Earnings8/14/2023Today9/26/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALPN CUSIPN/A CIK1626199 Webwww.alpineimmunesciences.com Phone(206) 788-4545Fax303-440-8399Employees126Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.00 High Stock Price Forecast$22.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+50.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,760,000.00 Net Margins-201.07% Pretax Margin-199.19% Return on Equity-33.44% Return on Assets-21.43% Debt Debt-to-Equity RatioN/A Current Ratio3.88 Quick Ratio3.88 Sales & Book Value Annual Sales$30.06 million Price / Sales19.61 Cash FlowN/A Price / Cash FlowN/A Book Value$3.90 per share Price / Book3.07Miscellaneous Outstanding Shares49,200,000Free Float28,390,000Market Cap$589.42 million OptionableNot Optionable Beta1.27 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Mitchell H. Gold M.D. (Age 55)Exec. Chairman & CEO Comp: $778.2kDr. Stanford Peng M.D. (Age 52)Ph.D., Pres and Head of R&D Comp: $751.2kMr. Paul Rickey (Age 44)Sr. VP, CFO, Treasurer & Sec. Comp: $577.1kDr. Wayne R. Gombotz (Age 64)Chief Technology Officer Temre JohnsonHead of IR & Corp. CommunicationsDr. Remy Durand Ph.D. (Age 38)Chief Bus. Officer Dr. Andrew Seth Sandler M.D. (Age 58)Chief Medical Officer More ExecutivesKey CompetitorsDyne TherapeuticsNYSE:DYNEnliven TherapeuticsNASDAQ:ELVNAvid BioservicesNASDAQ:CDMOBicycle TherapeuticsNASDAQ:BCYCPhathom PharmaceuticalsNASDAQ:PHATView All CompetitorsInstitutional OwnershipBarclays PLCSold 5,754 shares on 9/21/2023Ownership: 0.013%Affinity Asset Advisors LLCSold 129,000 shares on 8/21/2023Ownership: 0.242%California State Teachers Retirement SystemBought 1,763 shares on 8/21/2023Ownership: 0.021%Nuveen Asset Management LLCBought 61,948 shares on 8/16/2023Ownership: 0.195%Royal Bank of CanadaBought 1,315 shares on 8/15/2023Ownership: 0.006%View All Institutional Transactions ALPN Stock - Frequently Asked Questions Should I buy or sell Alpine Immune Sciences stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALPN shares. View ALPN analyst ratings or view top-rated stocks. What is Alpine Immune Sciences' stock price forecast for 2023? 5 Wall Street analysts have issued 1-year target prices for Alpine Immune Sciences' stock. Their ALPN share price forecasts range from $15.00 to $22.00. On average, they predict the company's share price to reach $18.00 in the next year. This suggests a possible upside of 50.3% from the stock's current price. View analysts price targets for ALPN or view top-rated stocks among Wall Street analysts. How have ALPN shares performed in 2023? Alpine Immune Sciences' stock was trading at $7.35 at the start of the year. Since then, ALPN stock has increased by 63.0% and is now trading at $11.98. View the best growth stocks for 2023 here. Are investors shorting Alpine Immune Sciences? Alpine Immune Sciences saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 2,520,000 shares, an increase of 28.6% from the August 15th total of 1,960,000 shares. Based on an average daily volume of 232,900 shares, the days-to-cover ratio is presently 10.8 days. View Alpine Immune Sciences' Short Interest. When is Alpine Immune Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our ALPN earnings forecast. How were Alpine Immune Sciences' earnings last quarter? Alpine Immune Sciences, Inc. (NASDAQ:ALPN) released its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.11. The biotechnology company had revenue of $8.59 million for the quarter, compared to analyst estimates of $8.08 million. Alpine Immune Sciences had a negative trailing twelve-month return on equity of 33.44% and a negative net margin of 201.07%. What ETF holds Alpine Immune Sciences' stock ? AdvisorShares Dorsey Wright Micro-Cap ETF holds 2,351 shares of ALPN stock, representing 0.65% of its portfolio. What other stocks do shareholders of Alpine Immune Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alpine Immune Sciences investors own include Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Abeona Therapeutics (ABEO), CymaBay Therapeutics (CBAY), Genocea Biosciences (GNCA), OPKO Health (OPK), SCYNEXIS (SCYX), Energy Transfer (ET) and Palatin Technologies (PTN). What is Alpine Immune Sciences' stock symbol? Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN." Who are Alpine Immune Sciences' major shareholders? Alpine Immune Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.78%), Great Point Partners LLC (7.01%), BlackRock Inc. (4.76%), Geode Capital Management LLC (1.29%), State Street Corp (1.19%) and Renaissance Technologies LLC (0.67%). Insiders that own company stock include Decheng Capital China Life Sci, Life Sciences Viii L Frazier, Mitchell Gold, Orbimed Advisors Llc, Robert E Conway and Robert E Conway. View institutional ownership trends. How do I buy shares of Alpine Immune Sciences? Shares of ALPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Alpine Immune Sciences' stock price today? One share of ALPN stock can currently be purchased for approximately $11.98. How much money does Alpine Immune Sciences make? Alpine Immune Sciences (NASDAQ:ALPN) has a market capitalization of $589.42 million and generates $30.06 million in revenue each year. The biotechnology company earns $-57,760,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. How many employees does Alpine Immune Sciences have? The company employs 126 workers across the globe. How can I contact Alpine Immune Sciences? Alpine Immune Sciences' mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The official website for the company is www.alpineimmunesciences.com. The biotechnology company can be reached via phone at (206) 788-4545, via email at laurence@gilmartinir.com, or via fax at 303-440-8399. This page (NASDAQ:ALPN) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpine Immune Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.